Sellas Life Sciences Gets Favorable Meeting Feedback From FDA
By Chris Wack
Sellas Life Sciences Group has received favorable Type C meeting feedback from the Food and Drug Administration for its lead product, galinpepimut-S.
The recently concluded Type C meeting with the FDA covered the biopharmaceutical company's Chemistry, Manufacturing, and Controls sections in a potential biologics license application for galinpepimut-S.
Sellas submitted a CMC Briefing Package to the FDA, which provided an up-to-date overview of the extensive work completed for the galinpepimut-S CMC program and commercial manufacturing and regulatory plans. The FDA reviewed the package of data and accompanying questions to the agency and responded with favorable guidance.
The FDA also agreed on the company's proposed stability data generation plan for the commercial presentation of galinpepimut-S. Galinpepimut-S is expected to be stored at 2 degrees Celsius to 8 degrees.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 13, 2023 09:22 ET (14:22 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks
-
Real Estate: Performance Continues to Be Driven by Interest-Rate Movements
-
Financial Services: Sector Doing Well Heading Into Rate-Cutting Cycle
-
Energy: OPEC Faces Hard Supply Decision in Latter Half of 2024
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024